<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="898">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149469</url>
  </required_header>
  <id_info>
    <org_study_id>8374</org_study_id>
    <nct_id>NCT05149469</nct_id>
  </id_info>
  <brief_title>Molecular Aspects of Preimplantation Genetic Diagnosis for NF1</brief_title>
  <acronym>NF1</acronym>
  <official_title>Evaluation of Preimplantation Genetic Diagnosis for Neurofibromatosis Type 1 (NF1), Emphasizing on the Molecular Aspects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurofibromatosis 1 (NF1) is a multisystem disorders characterized by skin abnormalities,&#xD;
      such as café-au-lait spots and neurofibromas, learning disabilities, skeletal anomalies and&#xD;
      vascular complications. Experience learns that this disorder is a great burden for patients.&#xD;
      NF1 is an autosomal dominant disorder with 50% risk of transmission. The penetrance is nearly&#xD;
      100%, but the expression varies greatly even within families, which makes it nearly&#xD;
      impossible to predict severity in offspring. Preimplantation genetic diagnosis (PGD) is a&#xD;
      reproductive option for couples at risk of transmitting NF1 to their offspring. We perform a&#xD;
      retrospective and observational multicentric study in the Maastricht University Medical&#xD;
      Center, the University Hospital of Brussel and Strasbourg University Hospital. Our specific&#xD;
      (and first) goal is to evaluate the molecular aspects of PGD for NF1 in an international&#xD;
      cohort of couples requesting PGD for NF1.&#xD;
&#xD;
      About 50% of the patients with NF1 have a de novo mutation that can complicate development of&#xD;
      a PGD test. Earlier studies from 1990 and 1992 have shown that de novo NF1 mutations usually&#xD;
      occur on the paternal allele. We want to confirm these findings with collected data from our&#xD;
      cohort. The high incidence of de novo mutations results in a higher chance of finding&#xD;
      mosaicism in patients or their parents. As a result of this, it can become apparent during&#xD;
      PGD test preparation that PGD treatment is no longer possible or indicated. The investigators&#xD;
      will evaluate these aspects of PGD for NF1 in our cohort.&#xD;
&#xD;
      They are also interested, as a second goal, in other aspects of PGD treatment for NF1, such&#xD;
      as the success rate in thier cohort. They expect the success rate to be the same as for other&#xD;
      autosomal dominant disorders&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of the molecular aspects of PGD for NF1 in a large European cohort.</measure>
    <time_frame>Files analysed retrospectively from from January 1, 2004 to June 30, 2021 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neurofibromatosis Type 1</condition>
  <eligibility>
    <study_pop>
      <textblock>
        - Major subjects (≥18 years old) who have been treated at the HUS for a preimplantation&#xD;
        diagnosis request for type 1 neurofibromatosis (confirmed by a molecular molecular&#xD;
        analysis) and who have benefited from preliminary analyzes, between 01/01/2004 and 30/06 /&#xD;
        2021&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Major subjects (≥18 years old)&#xD;
&#xD;
          -  Couples who have been treated at the HUS for a preimplantation diagnosis request for&#xD;
             type 1 neurofibromatosis (confirmed by a molecular molecular analysis) and who have&#xD;
             benefited from preliminary analyzes, between 01/01/2004 and 30/06 / 2021&#xD;
&#xD;
          -  Couple who, after receiving information, did not express their opposition to the reuse&#xD;
             of their data for the purposes of this research&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Couples who expressed their opposition to participating in the study&#xD;
&#xD;
          -  Subject under guardianship, curatorship or safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Céline MOUTOU, MD</last_name>
    <phone>33 3.69.55.34.65</phone>
    <email>celine.moutou@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Laboratoire de Diagnostic Génétique - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline MOUTOU, MD</last_name>
      <phone>33 3.69.55.34.65</phone>
      <email>celine.moutou@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Céline MOUTOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia LAUER ZILLHARDT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurofibromatosis Type 1</keyword>
  <keyword>NF1</keyword>
  <keyword>Preimplantation genetic diagnosis</keyword>
  <keyword>De novo mutation</keyword>
  <keyword>Mosaicism</keyword>
  <keyword>Molecular test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

